This article will detail the
original warnings the FDA issued regarding urogynecologic mesh when used in
pelvic organ prolapse surgical applications. According to an article titled An Appraisal of the Food and Drug
Administration Warning on Urogynecologic Surgical Mesh published in Current
Urology Reports (2012 13:231-239), permanent surgical mesh has been used in
various applications for several decades, having been used in the repair of
hernias since the 1950’s.
The FDA’s July 2011 report on
Urogynecologic Surgical Mesh defines surgical mesh as “a metallic or polymeric screen intended to be implanted to reinforce soft
tissue or bone where weakness exists.” Beginning in the 1970’s surgical
mesh made its appearance in abdominal surgeries for pelvic organ prolapse, then
in the 1980’s surgeons began using synthetic slings in the treatment of stress
urinary incontinence. It was not until 1996, however, that the FDA approved a type
of mesh particularly for use in stress urinary incontinence surgical
procedures. Some six years later, in 2002, the Federal Drug Administration
approved surgical mesh as an application for the treatment of pelvic organ
prolapse.